Rudolf M. Huber

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard et al. · The Lancet Oncology · 2015 · 1.4K citations

Medicine, Immunology, Oncology +17

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Dong‐Wan Kim, Marcello Tiseo, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2017 · 583 citations · Full text

Medicine, Oncology, Pharmacology +15

High Frequency Jet Ventilation in Interventional Fiberoptic Bronchoscopy

Hŭbert Haŭtmann, Fernando Gamarra, Markus O. Henke et al. · Anesthesia & Analgesia · 2000 · 320 citations

Medicine, Surgery, Anesthesia +16

Combined transcriptome and genome analysis of single micrometastatic cells

Christoph A. Klein, Stefan Seidl, Karina Petat‐Dutter et al. · Nature Biotechnology · 2002 · 304 citations

Life Sciences, Cell Biology, Molecular Biology +14

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

Petra Hoffknecht, Amanda Tufman, Thomas Wehler et al. · Journal of Thoracic Oncology · 2014 · 252 citations · Full text

Medicine, Oncology, Pharmacology +16